Regulation - Gilead Sciences, Johnson & Johnson

Filter

Popular Filters

Janssen submits sNDA for Olysio in combination with sofosbuvir

Janssen submits sNDA for Olysio in combination with sofosbuvir

08-05-2014

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson, has submitted…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioRegulationSovaldiUSA

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

17-01-2014

Since the US Food and Drug Administration’s breakthrough therapy designation (BTD) was put into effect…

GazyvaGilead SciencesImbruvicaJohnson & JohnsonPharmaceuticalRegulationRocheSovaldiUSA

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

Gilead and Johnson & Johnson get EU backing for HIV drugs Eviplera and Edurant, respectively

29-11-2011

In the first of two pieces of good news for HIV/AIDS drug developers, US biotech firm Gilead Sciences…

Anti-viralsEdurantEuropeEvipleraGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationTibotec

Company Spotlight

ImmunoGen

ImmunoGen

Back to top